Tandem Diabetes Care has picked up FDA clearance of its Tandem Mobi system, a tubeless automated insulin delivery device cleared for up to seven days of wear.
The new Tandem Mobi tubeless cartridge and infusion set converts the current Tandem Mobi pump into a tubeless device designed to simplify diabetes management by minimizing site changes.
The insulin pump system is now cleared for both tubeless and tubed insulin infusion options, which will make it the only tech to let users choose between wear options once it becomes commercially available in the U.S. in 2027.
Omnipod’s Insulet automated insulin delivery (AID) system only offers a tubeless wear option and cannot be worn for more than 72 hours.
“The Tandem Mobi insulin pump was originally designed to make different wear options possible, which now includes a tubeless option with up to 7 days of wear," said John Sheridan, president and CEO, in a statement.
“This clearance of the Tandem Mobi tubeless cartridge and infusion set creates even more possibilities for people living with diabetes, expanding the number of ways to experience the proven benefits of our Control-IQ+ AID technology.”
The company said that its tubeless infusion sets and cartridges will be available exclusively through the pharmacy for customers with pharmacy benefits.